FORECAST OF THE GLOBAL COAGULATION
FACTORS CONCENTRATES MARKET 2010 to 2025

REPORT COMPLETE

 

This report forecasts the global consumption of clotting factors (factors VIII, IX and von Willebrand factor, as well as bypassing agents) to 2025 in units and dollars in over 150 countries, under likely, pessimistic, and optimistic scenarios.

The goal of this study is to provide strategic insight to business development and production plans in the context of growing global demand and the emergence of new technologies such as longer half-life coagulation factor products and gene therapy.

Specific country information and assumptions were used to develop yearly forecasts of coagulation factor demand in each country from 2010 to 2025. The data distinguish the use of a) cryoprecipitate, b) plasma-derived coagulation factors and c) recombinant factor concentrates, including such novels agents as fusion-protein and long-acting factors. Dollar sales by product category have been estimated, using pricing assumptions over the forecast period.

The study does not take production constraints into consideration, but rather guide the clients towards the development of optimal production levels.

Statistical models have been developed to build sales forecasts of factor VIII, factor IX, von Willebrand factor and factor bypassing agents. Secondary data such as population, disease prevalence, patient registry, and other published sources, including proprietary MRB data were used to develop the initial baseline market profile and the forecasts.

The forecasts of factor VIII, factor IX, von Willebrand factor and inhibitor market may be purchased separately. The table of contents of the report and an order form are enclosed.

 


 

Forecast of the Global Coagulation Factors Concentrates Market
2010 to 2025

 

TABLE OF CONTENTS

 

Page

 

 

3

 

5

 

 

10

15

 

 

39

44

 

 

66

69

 

 

86

87

 

 

93

 

 

95

 

 

100

 

 

 

 

Introduction

 

Executive Summary

 

Factor VIII – Hemophilia A

Summary

Data

 

Factor IX – Hemophilia B

Summary

Data

 

vW Factor – von Willebrand Deficiency

Summary

Data

 

Inhibitor Bypass Agents

Summary

Data

 

Appendix 1

Description of the Model Function

 

Appendix 2

Users’ Instructions

 

Appendix 3

Directions for Model’s Assumptions Changes